To print: Select File and then Print from your browser's menu

Title: VEGF Trap Shows Activity in Patients with Advanced Ovarian Cancer: Presented at ASCO

"VEGF Trap Shows Activity in Patients with Advanced Ovarian Cancer: Presented at ASCO"

NEW YORK, NY -- June 12, 2007 -- Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents. The findings, which were presented at the American Society of Clinical Oncology's annual meeting (ASCO) in Chicago, may indicate a role for this targeted therapy in women with ovarian cancer who have exhausted all other options. To date, the trial has enrolled 162 patients with advanced ovarian cancer at 44 centers in twelve countries in Europe, Canada, and the United States. Favorable results were reported for 85% of participants after one month: 8% showed tumor shrinkage and 77% had stable disease. After fourteen weeks, 41% of patients continued to have stable disease. "The interim analysis of the Phase II data was very promising," said Dr. William P. Tew, an oncologist at Memorial Sloan-Kettering Cancer Center and the study's lead author. "As a result, we are continuing to recruit patients to complete the study." In this trial, VEGF Trap is administered intravenously as a single agent in one of two dose levels. It works by blocking the development of new blood vessels to the tumor (angiogenesis) which stops tumor growth and metastasis. It can also result in tumor shrinkage. VEGF Trap is generally well tolerated although both mild and severe side effects were reported. These included but were not limited to headache, fatigue, nausea, mild and severe hypertension, hoarseness, mild and severe protein in the urine, renal dysfunction, and a low incidence of bowel perforation (1%). "Ovarian cancer may be unusual among solid tumors because vascular-targeting agents like VEGF Trap appear to have significant single-agent activity in advanced ovarian cancer," said Dr. David R. Spriggs, Head of Solid Tumor Oncology at Memorial Sloan-Kettering and the study's senior author. "In most solid tumors, the efficacy of VEGF targeting is likely to be further enhanced by combining it with classic chemotherapy agents." Epithelial ovarian cancer is a disease in which malignant cells form in the tissue covering the ovary. About 85% to 90% of all ovarian cancers are this type. The American Cancer Society estimates 22,430 women in the United States will be diagnosed with ovarian cancer in 2007 and 15,280 will die. SOURCE: Memorial Sloan-Kettering Cancer Center

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.